Speaker Lecture Titles

Please see below the partial list of confirmed speakers

Last Name

First Name

Country

Title

AsheKarenUSATBA
AttemsJohannesUKThe overlap between Alzheimer and Lewy body pathologies
BarthélemyNicolasUSATau isoforms changes in brain and biofluids: diagnostic perspective and new insights on pathways involved in AD tauopathy
BezardErwanFranceAstonishing impact of patient-derived a-synuclein extracts and stealth recombinant a-synuclein polymorphs calls for careful thinking before developing therapeutics
BezprozvannyIlyaUSASigma 1 receptor as potential therapeutic target for AD
BlennowKajSwedenBlood biomarkers for Alzheimer’s disease – the promise for screening, diagnostics and therapy monitoring
Blurton JonesMathewUSAExamining the function of AD risk genes in human microglia and chimeric models
BrooksDavidUKDoes inflammation protect or exacerbate AD and PD progression
BueeLucFranceAnti-tau immunotherapy: side effects and specificity
CanavanMichelleIrelandAssociation of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment.
Association of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment
CheclerFrédéricFranceXBP1S-PINK1 functional interplay unravels molecular links between reticular stress and mitophagy
ClevelandDonUSAGenerating new neurons in the adult brain: therapeutic reversal of chemically induced Parkinson’s disease by converting astrocytes into nigral neurons
CuelloClaudio A.CanadaArguments for an early Alzheimer’s nano-Lithium therapy
CummingsJeffreyUSAAlzheimer Therapeutics: Potential Pipeline Predictions
De StrooperBartBelgiumThe microglia response to amyloid plaques
DiamondMarcUSAFunctional classification of tau prions and their relationship to tauopathies
DuffKarenUSAMechanisms of vulnerability to tauopathy
FalconBenjaminUKLinking amyloid structure to neurodegenerative disease
FändrichMarcusGermanyCryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer’s brain tissue
FrenkelDanIsraelPresenilin 1 role in mediating glia cell activity in Alzheimer’s disease
GalvinJamesUSADesigning Dementia Prevention Studies: Using Proxy Biomarkers to Identify At-Risk Individuals
GerwertKlausGermanyThe preclinical Alzheimer blood test using the immuno-Infrared-Sensor (iRS)
GiladiNirIsraelLRRK2-PD Vs. GBA-PD, an evolving story of genetic role in Parkinson’s disease
GoateAlisonUSAGenetic studies implicate microglial function in Alzheimer’s disease risk
GoldGabrielSwitzerlandMaking sense of mixed pathology in the oldest-old
GoldeToddUSATBA
GrowdonJohnUSAPET scans aid in the differential diagnosis of parkinsonian syndromes
HaassChristianGermanyMicroglial modulation in neurodegenerative disease – innovative therapies or devilish gambling?
HallidayGlendaAustraliaThe role of glia in progressing alpha-synuclein pathologies
HanssonOskarSwedenNovel fluid and PET imaging markers for neurodegenerative diseases
HardyJohnUKGenomic analysis of neurodegenerative disease
HenekaMichaelGermanyMutual interactions between immunity and degeneration in Alzheimer’s disease
HiguchiMakatoJapanMultimodal imaging of tau and alpha-synuclein pathologies
HoltzmanDavidUSARole of astrocyte-derived ApoE in tau-mediated neurodegeneration
HymanBradleyUSAComplexity of dissecting dementia progression in AD
IaedecolaCostantinoUSANeurovascular bases of neurodegeneration
IsacsonOleUSANeurons, astrocytes and microglia uniquely change their lipid load with a primary pathology in glycolipid and metabolic pathways in Parkinson’s disease.
IwatsuboTakeshiJapanPreclinical Alzheimer’s Clinical Trials: TRC-PAD and A4 in Japan
JackCliffordUSAThe future of imaging and biofluid Alzheimer’s biomarkers
JeonBeomseokKoreaGI synucleinothay as a biomarker in Parkinson’s disease: an update
KraincDimitriUSAMechanistic insights into familial and sporadic Parkinson’s disease: therapeutic implications
KulisevskyJaimeSpainCognitive Aspects of Huntington’s Disease
LaferlaFrankUSAMODEL-AD 2021 Overview: Developing the Next Generation of AD Mouse Models
LazarovOrlyUSAMolecular and cellular mechanisms underlying memory failure in Alzheimer’s disease
LeeVirginiaUSATBA
LeeSeung-JaeKoreaInterplay between synucleinopathy propagation and neuroinflammation
LemereCynthiaUSANovel, inducible conditional complement C3 mouse models to study neurodegeneration
LiptonStuartUSATBA
MarekKenUSANovel Biomarkers across the PD continuum – PPMI 2.0
MasliahEliezerUSATBA
MastersColinAustraliaPreclinical diagnosis of AD and  preventative therapeutic strategies
McLeanPamelaUSATherapeutic strategies to target alpha-synuclein levels in synucleinopathies
MichaelsonDaniel M.IsraelTBA
MorganDaveUSAComparison of different methods of inducing tau pathology in mice. Transgenesis, intracranial transduction and systemic tranduction
MorizaneAsukaJapanCell therapy for Parkinson’s disease with induced pluripotent stem cells
MorrisJohnUSARacial differences in molecular biomarkers for Alzheimer disease
MuckeLennartUSAMolecular and Cellular Modulators of Neural Network Dysfunction in Alzheimer’s Disease: From Tau to Microglia
MulthaupGerhardCanadaMetabolism of BACE1-mediated amyloid clearance products
NielsenHenriettaSwedenThe significance of apolipoprotein E levels in relation to neurodegenerative disease in humans
NordbergAgnetaSwedenCorrelation between neuroinflammation, tau pathology and synapse activity in neurodegenerative disorders
OuterioTiagoGermanyGlycation: an age-associated process that drives neurodegeneration in synucleinopathies
PetersenRonaldUSAAlzheimer’s Diagnosis in the Era of Biomarkers 2021
PoeweWernerAustriaDMT in PD – where do we stand?
PolymenidouMagdaliniSwitzerlandTBA
PradoMarcoCanadaCell type-specific cholinergic signalling improves plaque pathology and neuroinflammation in humanized knock-in APP mice
PriceJulieUSAPET methodology considerations for amyloid and tau imaging
RabinoviciGillUSAImpact of Amyloid PET on Health Outcomes: Update on the IDEAS study
RanumLauraUSATBA
RektorovaIrenaCzech RepublicCognitive impairment in Parkinson’s disease: neural correlates and treatment approaches
Rosa-NetoPedroCanadaStaging Alzheimer’s disease using biomarkers: application for clinical trials
SallowayStephenUSATBA
SchapiraAntonyUKNovel therapies for GBA-Parkinson disease
ScheltensPhilipThe NetherlandsThe ATN Framework for AD research set to work: real world evidence
SchlossmacherMichaelCanadaA redox function for parkin explains its selective neuroprotection in adult human brain
SchmidtReinholdAustriaMRI as a tool to study microstructural changes in aging and dementia
SchmitzTaylorCanadaIn vivo molecular imaging of cortical cholinergic denervation in preclinical Alzheimer’s disease
SchneiderJulieUSANeuropathologic insights into mechanisms of disease in Alzheimer’s and other Dementias
SegalMenahemIsraelPresenilin, oxidative stress and neurodegeneration
ShenJieUSAAPP and Presenilin in Alzheimer’s disease
SisodiaSamUSAInfluence of the Gut Microbiome on Aβ Amyloidosis and Neuroinflammation
SnyderPeterUSARetinal Biomarkers for Pre-Clinical Alzheimer’s disease: What we know, what we don’t know, and how to move forward
SoreqHermonaIsraelTransfer RNA fragments as novel biomarkers and therapeutic targets in Alzheimer’s disease
SpillantiniMaria GraziaUKInvestigating alpha-synuclein spreading from gut to brain
St. George-HyslopPeterCanadaDownstream TREM2 signalling in microglia
SuhYoo HunKoreaEffects of DHED and its Derivatives, Multitarget Candidates, for the Treatment of AD
ThalDietmarBelgiumNeuropathological classification strategies in Alzheimer’s disease and its impact on clinical practice and basic research.
ThinakaranGopalUSAThe functional role of the GWAS risk factor BIN1 in neurons and microglia
TrojanowskiJohn Q.USAMultiple Proteinopathy Disorders
Van BroeckhovenChristineBelgiumRare compound coding variants might increase risk in sporadic patients met neurodegenerative brain diseases
VassarRobertUSAAβ-accelerated neurodegeneration caused by novel Alzheimer’s-associated ACE variant R1279Q is rescued by angiotensin system inhibition
VillemagneVictorAustraliaAmyloid, tau and neuroinflammation imaging in Alzheimer’s disease
WeinerMichaelUSAValidating digital, biofluid, and neuroimaging biomarkers for clinical diagnosis and Alzheimer’s disease clinical trials: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
WeinerHowardUSAImmune mechanisms in Alzheimer’s disease and the role of the microbiome
WellingtonCherylCanadaThe role of high density lipoproteins in the vascular contributions to Alzheimer’s Disease
WilcockDonnaUSAAngiogenic dysregulation in vascular cognitive impairment and dementia
WilsonEdwardUnited StatesTREM1 as a Therapeutic Target for Alzheimer’s Disease
WongPhilipUSAIdentification of TDP-43 cryptic exons as functional fluid biomarkers for Alzheimer’s Disease and related Dementia
WszolekZbigniewUSAThe biomarker search for SCA3
Wyss-CorayTonyUSACirculatory factors as regulators of brain aging and neurodegeneration
XuHuaxiUSARoles for microglial Alzheimer’s risk genes in regulation of beta-amyloid metabolism and microglia function.
ZetterbergHenrikSwedenBlood biomarkers for Alzheimer’s disease and other neurodegenerative diseases – utility in clinical trials and practice
ZhengHuiUSATFEB-mediated lysosomal regulation and signaling in Alzheimer’s disease
ZhouJiaweiChinaEbf1 signaling in astrocytes drives CNS inflammation
ZlokovicBerislavUSATBA
BondiMarkUSAObjective subtle cognitive difficulties predict amyloid accumulation and neurodegeneration
GoedertMichelUKStructures of amyloid filaments from human brain
LiveseyFrederickUKInsights into pathogenesis of Alzheimer’s disease from human stem cell systems
MurrayMelissaUSASelective Vulnerability of the Cholinergic Hub in the Context of Aging and Alzheimer Disease Subtypes